Second-line treatment
PD
Twenty-eight patients received second-line treatment (76%), mainly PRRT (32%), carboplatin-etoposide (32%) or capecitabine/temozolomide (CAPTEM) (7%). RR was 15%, DCR 48%, and 22% experienced immediate PD. PFS and OS from the start of second-line treatment was 3.7 months (95% CI: 2.8–4.6 months) and 11.8 months (95% CI: 0–25 .1 months). Eleven and four patients received third- and fourth-line treatment.